nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—TEC—vagina—fallopian tube cancer	0.0107	0.0107	CbGeAlD
Dasatinib—BMX—epithelium—fallopian tube cancer	0.0105	0.0105	CbGeAlD
Dasatinib—SRMS—uterine cervix—fallopian tube cancer	0.00999	0.00999	CbGeAlD
Dasatinib—PTK6—uterine cervix—fallopian tube cancer	0.00979	0.00979	CbGeAlD
Dasatinib—STAT5B—epithelium—fallopian tube cancer	0.00933	0.00933	CbGeAlD
Dasatinib—STAT5B—uterine cervix—fallopian tube cancer	0.00926	0.00926	CbGeAlD
Dasatinib—BMX—uterus—fallopian tube cancer	0.00871	0.00871	CbGeAlD
Dasatinib—EPHB1—female gonad—fallopian tube cancer	0.00848	0.00848	CbGeAlD
Dasatinib—STAT5B—endometrium—fallopian tube cancer	0.00837	0.00837	CbGeAlD
Dasatinib—SRMS—uterus—fallopian tube cancer	0.00833	0.00833	CbGeAlD
Dasatinib—SIK3—uterine cervix—fallopian tube cancer	0.00832	0.00832	CbGeAlD
Dasatinib—SIK2—female reproductive system—fallopian tube cancer	0.00823	0.00823	CbGeAlD
Dasatinib—FRK—female reproductive system—fallopian tube cancer	0.00802	0.00802	CbGeAlD
Dasatinib—PKMYT1—female reproductive system—fallopian tube cancer	0.00802	0.00802	CbGeAlD
Dasatinib—ZAK—uterine cervix—fallopian tube cancer	0.00774	0.00774	CbGeAlD
Dasatinib—STAT5B—uterus—fallopian tube cancer	0.00771	0.00771	CbGeAlD
Dasatinib—BMPR1B—epithelium—fallopian tube cancer	0.00748	0.00748	CbGeAlD
Dasatinib—TXK—female reproductive system—fallopian tube cancer	0.00741	0.00741	CbGeAlD
Dasatinib—PTK6—female reproductive system—fallopian tube cancer	0.00733	0.00733	CbGeAlD
Dasatinib—PKMYT1—vagina—fallopian tube cancer	0.00725	0.00725	CbGeAlD
Dasatinib—ZAK—endometrium—fallopian tube cancer	0.007	0.007	CbGeAlD
Dasatinib—SIK3—uterus—fallopian tube cancer	0.00694	0.00694	CbGeAlD
Dasatinib—STAT5B—female reproductive system—fallopian tube cancer	0.00693	0.00693	CbGeAlD
Dasatinib—TESK1—uterine cervix—fallopian tube cancer	0.00684	0.00684	CbGeAlD
Dasatinib—STK36—uterine cervix—fallopian tube cancer	0.00673	0.00673	CbGeAlD
Dasatinib—EPHB3—uterine cervix—fallopian tube cancer	0.00673	0.00673	CbGeAlD
Dasatinib—TXK—vagina—fallopian tube cancer	0.0067	0.0067	CbGeAlD
Dasatinib—PTK6—female gonad—fallopian tube cancer	0.00667	0.00667	CbGeAlD
Dasatinib—PTK6—vagina—fallopian tube cancer	0.00663	0.00663	CbGeAlD
Dasatinib—LIMK2—uterine cervix—fallopian tube cancer	0.00651	0.00651	CbGeAlD
Dasatinib—ZAK—uterus—fallopian tube cancer	0.00645	0.00645	CbGeAlD
Dasatinib—STAT5B—female gonad—fallopian tube cancer	0.00631	0.00631	CbGeAlD
Dasatinib—CSK—uterine cervix—fallopian tube cancer	0.00627	0.00627	CbGeAlD
Dasatinib—SIK3—female reproductive system—fallopian tube cancer	0.00624	0.00624	CbGeAlD
Dasatinib—TESK1—endometrium—fallopian tube cancer	0.00619	0.00619	CbGeAlD
Dasatinib—HCK—uterine cervix—fallopian tube cancer	0.00619	0.00619	CbGeAlD
Dasatinib—BMPR1B—uterus—fallopian tube cancer	0.00618	0.00618	CbGeAlD
Dasatinib—EPHB3—endometrium—fallopian tube cancer	0.00609	0.00609	CbGeAlD
Dasatinib—STK36—endometrium—fallopian tube cancer	0.00609	0.00609	CbGeAlD
Dasatinib—TNK2—uterus—fallopian tube cancer	0.00606	0.00606	CbGeAlD
Dasatinib—LIMK2—endometrium—fallopian tube cancer	0.00589	0.00589	CbGeAlD
Dasatinib—RIPK2—epithelium—fallopian tube cancer	0.00587	0.00587	CbGeAlD
Dasatinib—RIPK2—uterine cervix—fallopian tube cancer	0.00582	0.00582	CbGeAlD
Dasatinib—ZAK—female reproductive system—fallopian tube cancer	0.0058	0.0058	CbGeAlD
Dasatinib—SIK1—uterine cervix—fallopian tube cancer	0.00568	0.00568	CbGeAlD
Dasatinib—SIK3—female gonad—fallopian tube cancer	0.00567	0.00567	CbGeAlD
Dasatinib—CSK—endometrium—fallopian tube cancer	0.00567	0.00567	CbGeAlD
Dasatinib—ERBB3—epithelium—fallopian tube cancer	0.00561	0.00561	CbGeAlD
Dasatinib—EPHB3—uterus—fallopian tube cancer	0.00561	0.00561	CbGeAlD
Dasatinib—HCK—endometrium—fallopian tube cancer	0.00559	0.00559	CbGeAlD
Dasatinib—ERBB3—uterine cervix—fallopian tube cancer	0.00557	0.00557	CbGeAlD
Dasatinib—BMPR1B—female reproductive system—fallopian tube cancer	0.00556	0.00556	CbGeAlD
Dasatinib—MAP3K19—female reproductive system—fallopian tube cancer	0.00556	0.00556	CbGeAlD
Dasatinib—MAP3K2—uterine cervix—fallopian tube cancer	0.00551	0.00551	CbGeAlD
Dasatinib—TNK2—female reproductive system—fallopian tube cancer	0.00545	0.00545	CbGeAlD
Dasatinib—LIMK2—uterus—fallopian tube cancer	0.00542	0.00542	CbGeAlD
Dasatinib—ZAK—female gonad—fallopian tube cancer	0.00527	0.00527	CbGeAlD
Dasatinib—RIPK2—endometrium—fallopian tube cancer	0.00526	0.00526	CbGeAlD
Dasatinib—ZAK—vagina—fallopian tube cancer	0.00524	0.00524	CbGeAlD
Dasatinib—MAPK14—epithelium—fallopian tube cancer	0.00523	0.00523	CbGeAlD
Dasatinib—CSK—uterus—fallopian tube cancer	0.00522	0.00522	CbGeAlD
Dasatinib—MAPK14—uterine cervix—fallopian tube cancer	0.00518	0.00518	CbGeAlD
Dasatinib—LCK—uterine cervix—fallopian tube cancer	0.00516	0.00516	CbGeAlD
Dasatinib—HCK—uterus—fallopian tube cancer	0.00515	0.00515	CbGeAlD
Dasatinib—SIK1—endometrium—fallopian tube cancer	0.00514	0.00514	CbGeAlD
Dasatinib—EPHA5—vagina—fallopian tube cancer	0.00513	0.00513	CbGeAlD
Dasatinib—TESK1—female reproductive system—fallopian tube cancer	0.00512	0.00512	CbGeAlD
Dasatinib—BMPR1B—female gonad—fallopian tube cancer	0.00506	0.00506	CbGeAlD
Dasatinib—STK36—female reproductive system—fallopian tube cancer	0.00504	0.00504	CbGeAlD
Dasatinib—EPHB3—female reproductive system—fallopian tube cancer	0.00504	0.00504	CbGeAlD
Dasatinib—BTK—female gonad—fallopian tube cancer	0.00503	0.00503	CbGeAlD
Dasatinib—BTK—vagina—fallopian tube cancer	0.005	0.005	CbGeAlD
Dasatinib—TNK2—female gonad—fallopian tube cancer	0.00496	0.00496	CbGeAlD
Dasatinib—EPHB4—epithelium—fallopian tube cancer	0.00496	0.00496	CbGeAlD
Dasatinib—JAK2—epithelium—fallopian tube cancer	0.00492	0.00492	CbGeAlD
Dasatinib—EPHB4—uterine cervix—fallopian tube cancer	0.00491	0.00491	CbGeAlD
Dasatinib—JAK2—uterine cervix—fallopian tube cancer	0.00488	0.00488	CbGeAlD
Dasatinib—LIMK2—female reproductive system—fallopian tube cancer	0.00488	0.00488	CbGeAlD
Dasatinib—EPHA2—epithelium—fallopian tube cancer	0.00486	0.00486	CbGeAlD
Dasatinib—EPHA2—uterine cervix—fallopian tube cancer	0.00482	0.00482	CbGeAlD
Dasatinib—FYN—uterine cervix—fallopian tube cancer	0.00481	0.00481	CbGeAlD
Dasatinib—SIK1—uterus—fallopian tube cancer	0.00473	0.00473	CbGeAlD
Dasatinib—STK35—female reproductive system—fallopian tube cancer	0.00473	0.00473	CbGeAlD
Dasatinib—MAP3K3—uterine cervix—fallopian tube cancer	0.0047	0.0047	CbGeAlD
Dasatinib—MAP4K5—uterine cervix—fallopian tube cancer	0.0047	0.0047	CbGeAlD
Dasatinib—CSK—female reproductive system—fallopian tube cancer	0.00469	0.00469	CbGeAlD
Dasatinib—EPHA4—uterus—fallopian tube cancer	0.00469	0.00469	CbGeAlD
Dasatinib—FGR—endometrium—fallopian tube cancer	0.00467	0.00467	CbGeAlD
Dasatinib—TESK1—female gonad—fallopian tube cancer	0.00466	0.00466	CbGeAlD
Dasatinib—ERBB3—uterus—fallopian tube cancer	0.00464	0.00464	CbGeAlD
Dasatinib—TESK1—vagina—fallopian tube cancer	0.00463	0.00463	CbGeAlD
Dasatinib—MAP3K2—uterus—fallopian tube cancer	0.00459	0.00459	CbGeAlD
Dasatinib—STK36—female gonad—fallopian tube cancer	0.00459	0.00459	CbGeAlD
Dasatinib—EPHB3—female gonad—fallopian tube cancer	0.00459	0.00459	CbGeAlD
Dasatinib—STK36—vagina—fallopian tube cancer	0.00456	0.00456	CbGeAlD
Dasatinib—EPHB3—vagina—fallopian tube cancer	0.00456	0.00456	CbGeAlD
Dasatinib—EPHB6—uterine cervix—fallopian tube cancer	0.00449	0.00449	CbGeAlD
Dasatinib—EPHB4—endometrium—fallopian tube cancer	0.00444	0.00444	CbGeAlD
Dasatinib—LIMK2—female gonad—fallopian tube cancer	0.00444	0.00444	CbGeAlD
Dasatinib—JAK2—endometrium—fallopian tube cancer	0.00441	0.00441	CbGeAlD
Dasatinib—LIMK2—vagina—fallopian tube cancer	0.00441	0.00441	CbGeAlD
Dasatinib—EPHA2—endometrium—fallopian tube cancer	0.00436	0.00436	CbGeAlD
Dasatinib—RIPK2—female reproductive system—fallopian tube cancer	0.00436	0.00436	CbGeAlD
Dasatinib—FYN—endometrium—fallopian tube cancer	0.00435	0.00435	CbGeAlD
Dasatinib—YES1—uterine cervix—fallopian tube cancer	0.00434	0.00434	CbGeAlD
Dasatinib—MAPK14—uterus—fallopian tube cancer	0.00432	0.00432	CbGeAlD
Dasatinib—LCK—uterus—fallopian tube cancer	0.0043	0.0043	CbGeAlD
Dasatinib—STK35—female gonad—fallopian tube cancer	0.0043	0.0043	CbGeAlD
Dasatinib—STK35—vagina—fallopian tube cancer	0.00427	0.00427	CbGeAlD
Dasatinib—CSK—female gonad—fallopian tube cancer	0.00427	0.00427	CbGeAlD
Dasatinib—SIK1—female reproductive system—fallopian tube cancer	0.00425	0.00425	CbGeAlD
Dasatinib—MAP4K5—endometrium—fallopian tube cancer	0.00425	0.00425	CbGeAlD
Dasatinib—MAP3K3—endometrium—fallopian tube cancer	0.00425	0.00425	CbGeAlD
Dasatinib—CSK—vagina—fallopian tube cancer	0.00425	0.00425	CbGeAlD
Dasatinib—HCK—female gonad—fallopian tube cancer	0.00422	0.00422	CbGeAlD
Dasatinib—SRC—epithelium—fallopian tube cancer	0.00421	0.00421	CbGeAlD
Dasatinib—EPHA4—female reproductive system—fallopian tube cancer	0.00421	0.00421	CbGeAlD
Dasatinib—HCK—vagina—fallopian tube cancer	0.00419	0.00419	CbGeAlD
Dasatinib—ABL2—female gonad—fallopian tube cancer	0.00419	0.00419	CbGeAlD
Dasatinib—SRC—uterine cervix—fallopian tube cancer	0.00418	0.00418	CbGeAlD
Dasatinib—ERBB3—female reproductive system—fallopian tube cancer	0.00417	0.00417	CbGeAlD
Dasatinib—ABL2—vagina—fallopian tube cancer	0.00416	0.00416	CbGeAlD
Dasatinib—MAP3K2—female reproductive system—fallopian tube cancer	0.00413	0.00413	CbGeAlD
Dasatinib—EPHB4—uterus—fallopian tube cancer	0.0041	0.0041	CbGeAlD
Dasatinib—EPHB6—endometrium—fallopian tube cancer	0.00406	0.00406	CbGeAlD
Dasatinib—FYN—uterus—fallopian tube cancer	0.00401	0.00401	CbGeAlD
Dasatinib—RIPK2—female gonad—fallopian tube cancer	0.00396	0.00396	CbGeAlD
Dasatinib—RIPK2—vagina—fallopian tube cancer	0.00394	0.00394	CbGeAlD
Dasatinib—YES1—endometrium—fallopian tube cancer	0.00393	0.00393	CbGeAlD
Dasatinib—MAP4K5—uterus—fallopian tube cancer	0.00392	0.00392	CbGeAlD
Dasatinib—MAPK14—female reproductive system—fallopian tube cancer	0.00388	0.00388	CbGeAlD
Dasatinib—SIK1—female gonad—fallopian tube cancer	0.00387	0.00387	CbGeAlD
Dasatinib—FGR—female reproductive system—fallopian tube cancer	0.00387	0.00387	CbGeAlD
Dasatinib—MAP2K5—uterine cervix—fallopian tube cancer	0.00384	0.00384	CbGeAlD
Dasatinib—EPHA4—female gonad—fallopian tube cancer	0.00383	0.00383	CbGeAlD
Dasatinib—EPHA4—vagina—fallopian tube cancer	0.00381	0.00381	CbGeAlD
Dasatinib—ERBB3—female gonad—fallopian tube cancer	0.00379	0.00379	CbGeAlD
Dasatinib—MAP3K2—female gonad—fallopian tube cancer	0.00376	0.00376	CbGeAlD
Dasatinib—CSF1R—uterine cervix—fallopian tube cancer	0.00375	0.00375	CbGeAlD
Dasatinib—EPHB4—female reproductive system—fallopian tube cancer	0.00368	0.00368	CbGeAlD
Dasatinib—JAK2—female reproductive system—fallopian tube cancer	0.00366	0.00366	CbGeAlD
Dasatinib—YES1—uterus—fallopian tube cancer	0.00362	0.00362	CbGeAlD
Dasatinib—EPHA2—female reproductive system—fallopian tube cancer	0.00361	0.00361	CbGeAlD
Dasatinib—FYN—female reproductive system—fallopian tube cancer	0.00361	0.00361	CbGeAlD
Dasatinib—PDGFRA—uterus—fallopian tube cancer	0.00355	0.00355	CbGeAlD
Dasatinib—MAPK14—female gonad—fallopian tube cancer	0.00353	0.00353	CbGeAlD
Dasatinib—MAP4K5—female reproductive system—fallopian tube cancer	0.00352	0.00352	CbGeAlD
Dasatinib—MAP3K3—female reproductive system—fallopian tube cancer	0.00352	0.00352	CbGeAlD
Dasatinib—FGR—female gonad—fallopian tube cancer	0.00352	0.00352	CbGeAlD
Dasatinib—LCK—female gonad—fallopian tube cancer	0.00352	0.00352	CbGeAlD
Dasatinib—MAPK14—vagina—fallopian tube cancer	0.00351	0.00351	CbGeAlD
Dasatinib—FGR—vagina—fallopian tube cancer	0.0035	0.0035	CbGeAlD
Dasatinib—LCK—vagina—fallopian tube cancer	0.0035	0.0035	CbGeAlD
Dasatinib—MAP2K5—endometrium—fallopian tube cancer	0.00348	0.00348	CbGeAlD
Dasatinib—KIT—epithelium—fallopian tube cancer	0.00344	0.00344	CbGeAlD
Dasatinib—KIT—uterine cervix—fallopian tube cancer	0.00341	0.00341	CbGeAlD
Dasatinib—CSF1R—endometrium—fallopian tube cancer	0.00339	0.00339	CbGeAlD
Dasatinib—FMO3—vagina—fallopian tube cancer	0.00338	0.00338	CbGeAlD
Dasatinib—PDGFRB—epithelium—fallopian tube cancer	0.00336	0.00336	CbGeAlD
Dasatinib—EPHB4—female gonad—fallopian tube cancer	0.00335	0.00335	CbGeAlD
Dasatinib—EPHB4—vagina—fallopian tube cancer	0.00333	0.00333	CbGeAlD
Dasatinib—PDGFRB—uterine cervix—fallopian tube cancer	0.00333	0.00333	CbGeAlD
Dasatinib—JAK2—female gonad—fallopian tube cancer	0.00333	0.00333	CbGeAlD
Dasatinib—JAK2—vagina—fallopian tube cancer	0.00331	0.00331	CbGeAlD
Dasatinib—EPHA2—female gonad—fallopian tube cancer	0.00329	0.00329	CbGeAlD
Dasatinib—FYN—female gonad—fallopian tube cancer	0.00328	0.00328	CbGeAlD
Dasatinib—EPHA2—vagina—fallopian tube cancer	0.00327	0.00327	CbGeAlD
Dasatinib—FYN—vagina—fallopian tube cancer	0.00326	0.00326	CbGeAlD
Dasatinib—YES1—female reproductive system—fallopian tube cancer	0.00325	0.00325	CbGeAlD
Dasatinib—MAP3K3—female gonad—fallopian tube cancer	0.00321	0.00321	CbGeAlD
Dasatinib—MAP4K5—female gonad—fallopian tube cancer	0.00321	0.00321	CbGeAlD
Dasatinib—PDGFRA—female reproductive system—fallopian tube cancer	0.00319	0.00319	CbGeAlD
Dasatinib—MAP4K5—vagina—fallopian tube cancer	0.00319	0.00319	CbGeAlD
Dasatinib—MAP3K3—vagina—fallopian tube cancer	0.00319	0.00319	CbGeAlD
Dasatinib—SRC—female reproductive system—fallopian tube cancer	0.00313	0.00313	CbGeAlD
Dasatinib—CSF1R—uterus—fallopian tube cancer	0.00313	0.00313	CbGeAlD
Dasatinib—KIT—endometrium—fallopian tube cancer	0.00308	0.00308	CbGeAlD
Dasatinib—EPHB6—female gonad—fallopian tube cancer	0.00306	0.00306	CbGeAlD
Dasatinib—EPHB6—vagina—fallopian tube cancer	0.00305	0.00305	CbGeAlD
Dasatinib—PDGFRB—endometrium—fallopian tube cancer	0.00301	0.00301	CbGeAlD
Dasatinib—ABL1—uterine cervix—fallopian tube cancer	0.00296	0.00296	CbGeAlD
Dasatinib—YES1—female gonad—fallopian tube cancer	0.00296	0.00296	CbGeAlD
Dasatinib—YES1—vagina—fallopian tube cancer	0.00294	0.00294	CbGeAlD
Dasatinib—PDGFRA—female gonad—fallopian tube cancer	0.0029	0.0029	CbGeAlD
Dasatinib—PDGFRA—vagina—fallopian tube cancer	0.00289	0.00289	CbGeAlD
Dasatinib—MAP2K5—female reproductive system—fallopian tube cancer	0.00288	0.00288	CbGeAlD
Dasatinib—SRC—female gonad—fallopian tube cancer	0.00285	0.00285	CbGeAlD
Dasatinib—KIT—uterus—fallopian tube cancer	0.00284	0.00284	CbGeAlD
Dasatinib—CSF1R—female reproductive system—fallopian tube cancer	0.00281	0.00281	CbGeAlD
Dasatinib—PDGFRB—uterus—fallopian tube cancer	0.00277	0.00277	CbGeAlD
Dasatinib—ABL1—endometrium—fallopian tube cancer	0.00268	0.00268	CbGeAlD
Dasatinib—MAP2K5—female gonad—fallopian tube cancer	0.00262	0.00262	CbGeAlD
Dasatinib—MAP2K5—vagina—fallopian tube cancer	0.0026	0.0026	CbGeAlD
Dasatinib—CSF1R—female gonad—fallopian tube cancer	0.00256	0.00256	CbGeAlD
Dasatinib—KIT—female reproductive system—fallopian tube cancer	0.00255	0.00255	CbGeAlD
Dasatinib—CSF1R—vagina—fallopian tube cancer	0.00254	0.00254	CbGeAlD
Dasatinib—PDGFRB—female reproductive system—fallopian tube cancer	0.00249	0.00249	CbGeAlD
Dasatinib—ABL1—uterus—fallopian tube cancer	0.00247	0.00247	CbGeAlD
Dasatinib—KIT—female gonad—fallopian tube cancer	0.00232	0.00232	CbGeAlD
Dasatinib—KIT—vagina—fallopian tube cancer	0.00231	0.00231	CbGeAlD
Dasatinib—PDGFRB—female gonad—fallopian tube cancer	0.00227	0.00227	CbGeAlD
Dasatinib—PDGFRB—vagina—fallopian tube cancer	0.00225	0.00225	CbGeAlD
Dasatinib—ABL1—female reproductive system—fallopian tube cancer	0.00222	0.00222	CbGeAlD
Dasatinib—CYP1B1—uterus—fallopian tube cancer	0.00209	0.00209	CbGeAlD
Dasatinib—ABL1—female gonad—fallopian tube cancer	0.00202	0.00202	CbGeAlD
Dasatinib—ABL1—vagina—fallopian tube cancer	0.00201	0.00201	CbGeAlD
Dasatinib—CYP1B1—female reproductive system—fallopian tube cancer	0.00188	0.00188	CbGeAlD
Dasatinib—ABCG2—uterine cervix—fallopian tube cancer	0.00187	0.00187	CbGeAlD
Dasatinib—CYP1A1—epithelium—fallopian tube cancer	0.00179	0.00179	CbGeAlD
Dasatinib—CYP1A1—uterine cervix—fallopian tube cancer	0.00177	0.00177	CbGeAlD
Dasatinib—CYP3A5—uterine cervix—fallopian tube cancer	0.00174	0.00174	CbGeAlD
Dasatinib—CYP1B1—female gonad—fallopian tube cancer	0.00171	0.00171	CbGeAlD
Dasatinib—ABCG2—endometrium—fallopian tube cancer	0.00169	0.00169	CbGeAlD
Dasatinib—ABCG2—uterus—fallopian tube cancer	0.00156	0.00156	CbGeAlD
Dasatinib—CYP1A1—uterus—fallopian tube cancer	0.00148	0.00148	CbGeAlD
Dasatinib—CYP1A1—female reproductive system—fallopian tube cancer	0.00133	0.00133	CbGeAlD
Dasatinib—ABCG2—female gonad—fallopian tube cancer	0.00127	0.00127	CbGeAlD
Dasatinib—ABCG2—vagina—fallopian tube cancer	0.00127	0.00127	CbGeAlD
Dasatinib—CYP1A1—female gonad—fallopian tube cancer	0.00121	0.00121	CbGeAlD
Dasatinib—CYP1A1—vagina—fallopian tube cancer	0.0012	0.0012	CbGeAlD
Dasatinib—CYP3A5—female gonad—fallopian tube cancer	0.00118	0.00118	CbGeAlD
Dasatinib—CYP3A5—vagina—fallopian tube cancer	0.00118	0.00118	CbGeAlD
Dasatinib—CYP3A4—female reproductive system—fallopian tube cancer	0.000976	0.000976	CbGeAlD
Dasatinib—ABCB1—epithelium—fallopian tube cancer	0.00093	0.00093	CbGeAlD
Dasatinib—ABCB1—uterine cervix—fallopian tube cancer	0.000922	0.000922	CbGeAlD
Dasatinib—ABCB1—endometrium—fallopian tube cancer	0.000834	0.000834	CbGeAlD
Dasatinib—ABCB1—uterus—fallopian tube cancer	0.000768	0.000768	CbGeAlD
Dasatinib—ABCB1—female reproductive system—fallopian tube cancer	0.000691	0.000691	CbGeAlD
Dasatinib—ABCB1—female gonad—fallopian tube cancer	0.000629	0.000629	CbGeAlD
Dasatinib—ABCB1—vagina—fallopian tube cancer	0.000625	0.000625	CbGeAlD
